NASDAQ:ABSI Absci Q1 2025 Earnings Report $3.09 +0.04 (+1.31%) Closing price 04:00 PM EasternExtended Trading$3.05 -0.04 (-1.29%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Absci EPS ResultsActual EPSN/AConsensus EPS -$0.23Beat/MissN/AOne Year Ago EPSN/AAbsci Revenue ResultsActual RevenueN/AExpected Revenue$1.07 millionBeat/MissN/AYoY Revenue GrowthN/AAbsci Announcement DetailsQuarterQ1 2025Date5/13/2025TimeAfter Market ClosesConference Call DateTuesday, May 13, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Remove Ads Absci Earnings HeadlinesKeyBanc Reaffirms Their Buy Rating on AbSci (ABSI)April 16 at 3:48 PM | markets.businessinsider.comAbsci price target raised to $9 from $5 at KeyBancApril 16 at 3:48 PM | markets.businessinsider.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 17, 2025 | Paradigm Press (Ad)Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025April 14 at 4:05 PM | globenewswire.comAbsci's (ABSI) "Buy" Rating Reiterated at Needham & Company LLCApril 12, 2025 | americanbankingnews.com3ABSI : Absci Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)April 9, 2025 | benzinga.comSee More Absci Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Absci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Absci and other key companies, straight to your email. Email Address About AbsciAbsci (NASDAQ:ABSI) operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.View Absci ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth Ahead Upcoming Earnings HDFC Bank (4/18/2025)Intuitive Surgical (4/22/2025)Tesla (4/22/2025)Chubb (4/22/2025)Canadian National Railway (4/22/2025)Capital One Financial (4/22/2025)Danaher (4/22/2025)Elevance Health (4/22/2025)General Electric (4/22/2025)Lockheed Martin (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
